ArticleCell2020
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.
3 registry-linked trialsAbstract read
In one paragraph
Article in Cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 228 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
228citing papers in PubMed, 5 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
TEMPUS GEMINI NSCLC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Non-Small Cell Lung Cancer (NSCLC)
Implementation of Up-front ctDNA Analysis Into Lung Cancer Care and Development of Liquid Biopsy-based Decision Support Models - the Lungmarker² Study
TEMPUS PHOENIX HNSCC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Who cites it
228 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- The Predictive Role of ctDNA and CTCs in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2026Pooled it
- Prognostic utility of circulating tumor DNA assessment in immune checkpoint inhibitor-treated advanced non-small cell lung cancer: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis.The oncologist · 2025Pooled it
- Effect of acupuncture and moxibustion on the immune function of patients with malignant tumors: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Deciphering radiological stable disease to immune checkpoint inhibitors.Annals of oncology : official journal of the European Society for Medical Oncology · 2022Pooled it
- Trial
- CD8 PET imaging with [Journal for immunotherapy of cancer · 2026Trial
- Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM).Nature communications · 2026Trial
- Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer.Breast cancer research and treatment · 2025Trial
- Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial.Signal transduction and targeted therapy · 2024Trial
- Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432).Signal transduction and targeted therapy · 2024Trial
- Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2024Trial
- Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study.Nature communications · 2024Trial
- The activity and immune dynamics of PD-1 inhibition on high-risk pulmonary ground glass opacity lesions: insights from a single-arm, phase II trial.Signal transduction and targeted therapy · 2024Trial
- Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study.Cancer communications (London, England) · 2024Trial
- Trial
- Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial.Journal for immunotherapy of cancer · 2022Trial
- Circulating Tumor DNA Monitoring Reveals Molecular Progression before Radiologic Progression in a Real-life Cohort of Patients with Advanced Non-small Cell Lung Cancer.Cancer research communications · 2022Trial
- Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.Nature medicine · 2022Trial
- Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy.JAMA network open · 2022Trial
168 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
32 authors.
Barzin Y NabetDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA; Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
Mohammad S EsfahaniDivision of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
Everett J ModingDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA; Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
Emily G HamiltonDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA; Program in Cancer Biology, Stanford University, Stanford, CA, USA.
Jacob J ChabonDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA.
Hira RizviDruckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Chloe B SteenStanford Cancer Institute, Stanford University, Stanford, CA, USA.
Aadel A ChaudhuriDepartment of Radiation Oncology, Department of Genetics, Washington University School of Medicine, St. Louis, MO, USA.
Chih Long LiuStanford Cancer Institute, Stanford University, Stanford, CA, USA; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
Angela B HuiDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA; Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
Diego AlmanzaDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA; Program in Cancer Biology, Stanford University, Stanford, CA, USA.
Henning StehrDepartment of Pathology, Stanford University, Stanford, CA, USA.
Linda GojenolaDepartment of Pathology, Stanford University, Stanford, CA, USA.
Rene F BonillaDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
Michael C JinDivision of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
Young-Jun JeonDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA; Stanford Cancer Institute, Stanford University, Stanford, CA, USA; Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, Republic of Korea.
Diane TsengDivision of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
Cailian LiuLudwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Taha MerghoubLudwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell School of Medicine, New York, NY, USA; Parker Institute for Cancer Immunotherapy at MSK, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Joel W NealStanford Cancer Institute, Stanford University, Stanford, CA, USA; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
Heather A WakeleeStanford Cancer Institute, Stanford University, Stanford, CA, USA; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
Sukhmani K PaddaStanford Cancer Institute, Stanford University, Stanford, CA, USA; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
Kavitha J RamchandranStanford Cancer Institute, Stanford University, Stanford, CA, USA; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
Millie DasStanford Cancer Institute, Stanford University, Stanford, CA, USA; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, CA, USA; Department of Medicine, VA Palo Alto Health Care System, Palo Alto, CA, USA.
Andrew J PlodkowskiDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Christopher YooDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
Emily L ChenDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
Ryan B KoDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
Aaron M NewmanStanford Cancer Institute, Stanford University, Stanford, CA, USA; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA; Department of Biomedical Data Science, Stanford University, Stanford, CA, USA.
Matthew D HellmannDruckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell School of Medicine, New York, NY, USA; Parker Institute for Cancer Immunotherapy at MSK, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: hellmanm@mskcc.org.
Ash A AlizadehStanford Cancer Institute, Stanford University, Stanford, CA, USA; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, CA, USA; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA. Electronic address: arasha@stanford.edu.
Maximilian DiehnDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA; Stanford Cancer Institute, Stanford University, Stanford, CA, USA; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA. Electronic address: diehn@stanford.edu.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MLeveraging innovative technologies in basic and clinical cancer researchT32CA009302 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI, Aaron M Newman · 1985 to 2026
$19.1MMolecularly-based outcome and toxicity prediction after radiotherapy for lung cancerR01CA254179 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, DIEHN, MAXIMILIAN · 2020 to 2024
$3.1MAnalysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancerR01CA244526 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, DIEHN, MAXIMILIAN · 2020 to 2024
$3.0MA Genomic Framework for Molecular Risk Prediction & Individualized Lymphoma TherapyR01CA233975 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, DIEHN, MAXIMILIAN · 2019 to 2023
$2.8MDeveloping a genomic approach for cancer screeningDP2CA186569 · NCI · STANFORD UNIVERSITY · PI DIEHN, MAXIMILIAN · 2013 to 2013
$2.4MCancer Systems Biology Scholars ProgramR25CA180993 · NCI · STANFORD UNIVERSITY · PI PLEVRITIS, SYLVIA KATINA · 2014 to 2018
$2.2MNoninvasive monitoring of lung cancer patients treated with radiotherapyR01CA188298 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, DIEHN, MAXIMILIAN · 2015 to 2019
$1.8MNCI NIH HHS DP2 CA186569NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA188298NCI NIH HHS R01 CA233975NCI NIH HHS R01 CA244526NCI NIH HHS R01 CA254179NCI NIH HHS R25 CA180993NCI NIH HHS T32 CA009302
Abstract
Although treatment of non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs) can produce remarkably durable responses, most patients develop early disease progression. Furthermore, initial response assessment by conventional imaging is often unable to identify which patients will achieve durable clinical benefit (DCB). Here, we demonstrate that pre-treatment circulating tumor DNA (ctDNA) and peripheral CD8 T cell levels are independently associated with DCB. We further show that ctDNA dynamics after a single infusion can aid in identification of patients who will achieve DCB. Integrating these determinants, we developed and validated an entirely noninvasive multiparameter assay (DIREct-On, Durable Immunotherapy Response Estimation by immune profiling and ctDNA-On-treatment) that robustly predicts which patients will achieve DCB with higher accuracy than any individual feature. Taken together, these results demonstrate that integrated ctDNA and circulating immune cell profiling can provide accurate, noninvasive, and early forecasting of ultimate outcomes for NSCLC patients receiving ICIs.
Indexed as
AdultAntineoplastic Agents, ImmunologicalB7-H1 AntigenBiomarkers, PharmacologicalBiomarkers, TumorCarcinoma, Non-Small-Cell LungCD8-Positive T-LymphocytesCirculating Tumor DNAFemaleHumansImmune Checkpoint InhibitorsImmunotherapyLung NeoplasmsMaleMiddle AgedProgrammed Cell Death 1 ReceptorAntineoplastic Agents, ImmunologicalB7-H1 AntigenBiomarkers, PharmacologicalBiomarkers, TumorCirculating Tumor DNAImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptorcirculating tumor DNAimmune checkpoint inhibitionimmunotherapyliquid biopsynon-small cell lung cancerresponse classification
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.